Switch theme
Sign up to access all valuation multiples
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
2018
728
LTM Revenue $499M
LTM EBITDA $95.2M
$4.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TransMedics has a last 12-month revenue (LTM) of $499M and a last 12-month EBITDA of $95.2M.
In the most recent fiscal year, TransMedics achieved revenue of $442M and an EBITDA of $69.9M.
TransMedics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TransMedics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $499M | XXX | $442M | XXX | XXX | XXX |
| Gross Profit | $299M | XXX | $262M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $95.2M | XXX | $69.9M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $52.9M | XXX | $37.5M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $50.0M | XXX | $35.5M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $173M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TransMedics's stock price is $127.
TransMedics has current market cap of $4.3B, and EV of $4.5B.
See TransMedics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.5B | $4.3B | XXX | XXX | XXX | XXX | $1.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TransMedics has market cap of $4.3B and EV of $4.5B.
TransMedics's trades at 10.2x EV/Revenue multiple, and 64.4x EV/EBITDA.
Equity research analysts estimate TransMedics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TransMedics has a P/E ratio of 86.0x.
See valuation multiples for TransMedics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.3B | XXX | $4.3B | XXX | XXX | XXX |
| EV (current) | $4.5B | XXX | $4.5B | XXX | XXX | XXX |
| EV/Revenue | 9.0x | XXX | 10.2x | XXX | XXX | XXX |
| EV/EBITDA | 47.3x | XXX | 64.4x | XXX | XXX | XXX |
| EV/EBIT | 85.1x | XXX | 120.1x | XXX | XXX | XXX |
| EV/Gross Profit | 15.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 86.0x | XXX | 121.1x | XXX | XXX | XXX |
| EV/FCF | -231.5x | XXX | -55.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTransMedics's last 12 month revenue growth is 26%
TransMedics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
TransMedics's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TransMedics's rule of X is 84% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TransMedics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 84% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TransMedics acquired XXX companies to date.
Last acquisition by TransMedics was XXXXXXXX, XXXXX XXXXX XXXXXX . TransMedics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TransMedics founded? | TransMedics was founded in 2018. |
| Where is TransMedics headquartered? | TransMedics is headquartered in United States of America. |
| How many employees does TransMedics have? | As of today, TransMedics has 728 employees. |
| Who is the CEO of TransMedics? | TransMedics's CEO is Dr. Waleed H. Hassanein, M.D.. |
| Is TransMedics publicy listed? | Yes, TransMedics is a public company listed on NAS. |
| What is the stock symbol of TransMedics? | TransMedics trades under TMDX ticker. |
| When did TransMedics go public? | TransMedics went public in 2019. |
| Who are competitors of TransMedics? | Similar companies to TransMedics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of TransMedics? | TransMedics's current market cap is $4.3B |
| What is the current revenue of TransMedics? | TransMedics's last 12 months revenue is $499M. |
| What is the current revenue growth of TransMedics? | TransMedics revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of TransMedics? | Current revenue multiple of TransMedics is 9.0x. |
| Is TransMedics profitable? | Yes, TransMedics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TransMedics? | TransMedics's last 12 months EBITDA is $95.2M. |
| What is TransMedics's EBITDA margin? | TransMedics's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of TransMedics? | Current EBITDA multiple of TransMedics is 47.3x. |
| What is the current FCF of TransMedics? | TransMedics's last 12 months FCF is -$19.5M. |
| What is TransMedics's FCF margin? | TransMedics's last 12 months FCF margin is -4%. |
| What is the current EV/FCF multiple of TransMedics? | Current FCF multiple of TransMedics is -231.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
